INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

PROPOSED CHANGE OF COMPANY NAME; AND PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL

The Board proposes to:

(a) change the English name of the Company from "Innovative Pharmaceutical Biotech Limited" to "Starcoin Group Limited", and to adopt the Chinese name of "星太鏈集團有限公司" as the secondary name of the Company in place of the existing name of "領航醫藥及生物科技有限公司"; and

(b) increase the authorised share capital of the Company from HK$500,000,000 divided into 50,000,000,000 Shares to HK$1,200,000,000 divided into 120,000,000,000 Shares.

PROPOSED CHANGE OF COMPANY NAME

The board (the "**Board**") of directors (the "**Director(s)**") of Innovative Pharmaceutical Biotech Limited (the "**Company**", together with its subsidiaries, the "**Group**") proposes to change the English name of the Company from "Innovative Pharmaceutical Biotech Limited" to "Starcoin Group Limited", and to adopt the Chinese name of "星太鏈集團有限公司" as the secondary name of the Company in place of the existing name of "領航醫藥及生物科技有限公司" (the "**Proposed Change of Company Name**").

Conditions for the Proposed Change of Company Name

The Proposed Change of Company Name is conditional upon the following conditions having been satisfied:

(i) the passing of a special resolution by the shareholders of the Company (the "**Shareholders**") at the forthcoming annual general meeting (the "**AGM**") to consider and, if thought fit, approve the Proposed Change of Company Name; and

(ii) the Registrar of Companies in Bermuda granting approval for the Proposed Change of Company Name by issuing a certificate of change of name.

Subject to the satisfaction of the conditions set out above, the Proposed Change of Company Name will take effect upon the date of the issue of a certificate of change of name by the Registrar of Companies in Bermuda confirming that the new names have been registered. The Company will then carry out the necessary filing procedures with the Companies Registry in Hong Kong.

Reasons for the Proposed Change of Company Name

The Board considers that the new English and Chinese names of the Company can provide the Company with a fresh new corporate image and identity, which will better reflect and strengthen its future business development. The Board is therefore of the view that the Proposed Change of Company Name is in the interests of the Company and the Shareholders as a whole.

Effects of the Proposed Change of Company Name

The Proposed Change of Company Name will not affect any rights of the Shareholders or the Company's daily business operation or its financial position. All existing share certificates of the Company in issue bearing the existing name or former name of the Company shall, upon the Proposed Change of Company Name becoming effective, continue to be good evidence of legal title to such shares and will remain valid for trading, settlement, registration and delivery for the same number of shares in the new names of the Company. There will not be any arrangement for free exchange of the existing share certificates for new share certificates bearing the new names of the Company. Upon the Proposed Change of Company Name becoming effective, all new share certificates will be issued only in the new names of the Company.

In addition, subject to confirmation by The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), the stock short names of the Company for trading in the securities on the Stock Exchange and the logo of the Company will also be changed after the Proposed Change of Company Name becoming effective.

Further announcement(s) will be made by the Company in relation to the effective date of the Proposed Change of Company Name and details of the change of the stock short names, logo and website of the Company. The stock code of the Company will remain as "399".

PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL

The Board also proposes to increase the authorised share capital of the Company from HK$500,000,000 divided into 50,000,000,000 shares of the Company (the "**Share(s)**") to HK$1,200,000,000 divided into 120,000,000,000 Shares by the creation of an additional 70,000,000,000 Shares which shall rank pari passu in all respects with the existing Shares (the "**Proposed Increase in Authorised Share Capital**"). The Proposed Increase in Authorised Share Capital is subject to the approval of the Shareholders by way of an ordinary resolution at the AGM.

As at the date of this announcement, 1,845,757,924 Shares are in issue and 48,154,242,076 Shares are authorised but unissued. In order to accommodate the future expansion and growth of the Group and to provide the Company with greater flexibility to raise funds in the future, the Board believes the Proposed Increase in Authorised Share Capital is in the interests of the Company and the Shareholders as a whole.

As at the date of this announcement, the Company does not have any immediate plan to conduct any equity fund raising by issuing new Shares from any part of the increased authorised share capital and may or may not further issue new Shares in the future depending on market conditions and the financial needs of the Company.

GENERAL

At the AGM, a special resolution will be proposed for the Shareholders to consider, and if appropriate, to approve the Proposed Change of Company Name and an ordinary resolution will be proposed for the Shareholders to consider, and if appropriate, to approve the Proposed Increase in Authorised Share Capital.

A circular containing, among other things, further details concerning the Proposed Change of Company Name and the Proposed Increase in Authorised Share Capital and a notice convening the AGM will be dispatched to the Shareholders in due course. Further announcement(s) will be made by the Company to inform the Shareholders of the results of the AGM, the effective date of the Proposed Change of Company Name, the new stock short names of the Company for trading on the Stock Exchange and the Proposed Increase in Authorised Share Capital as and when appropriate.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Yeung Yung
Chairman

Hong Kong, 2 July 2025

As at the date of this announcement, the Board comprises Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director), and Ms. Sun Sizheng (independent non-executive Director).